CD14 and breast carcinoma: Higher levels of T cells at early stages of differentiation have been detected in breast cancer patients (p < 0.05) (Speigl et al., 2017), and CD14+ myeloid cells from breast cancer patients have been shown to have enhanced ability to suppress autologous T-cell proliferation (Speigl et al., 2017).